British Society of Cardiovascular Magnetic Resonance Research Group (BSCMR-RG)
The BSCMR-RG was formed in September 2012. The aim of the RG is to systematically and comprehensively coordinate clinical CMR research in the UK through well-designed and executed multicentre studies leading to high-quality clinical evidence that will influence clinical practice.
The BSCMR-RG is co-chaired by Stefan Neubauer (Oxford, right) and Gerry McCann (Leicester). The RG has seven task forces, which each include active researchers from throughout the UK. The RG has met on six occasions and several grant applications have already been submitted for funding.
The Task Forces and leads are:
- Chronic ischemic heart disease Lead: Prof. John Greenwood, Leeds
- Acute coronary syndromes Lead: Prof. Colin Berry, Glasgow
- Cardiomyopathies Lead: Prof. Stefan Neubauer, Oxford
- Heart failure Lead: Dr Francisco Leyva, Birmingham
- Valvular heart disease Lead: Dr Gerry McCann, Leicester
- Congenital and interventional CMR Lead: Prof. Reza Razavi, London
- Tissue characterisation Lead: Prof. James Moon, London
In addition Prof. Rene Botnar (London) is a member of the RG, and Prof. Sven Plein (Leeds/KCL, Prof. Steffen Petersen (London), Dr Chiara Bucciarelli-Ducci (Bristol) and Dr Matthias Schmitt (Manchester) have recently been added as further members of the group.
Anyone who wishes to become involved in multicentre CMR research should contact the respective task force lead in the disease area of interest. If you are planning a multicentre study and wish to have this endorsed by the BSCMR RG please download the application form (BSCMR – Research endorsement document) and submit it to the relevant task force lead.
Active UK multicentre CMR studies are listed in the table below.
Table 1: Currently active UK based multicentre CMR studies
|Study||PI||Funder||Objective||No Pts||Status||Expected completion||Centres||Comments|
|CHD – TF Lead J Greenwood|
|MR-INFORM||Nagel (KCL)||King’s BRC Bayer||Compare strategy of 1.5T MR v FFR management in stable CAD||918||Recruiting. Started Dec 2010||Completed Aug 15||15 centres: UK, Germany, Portugal, Aus||In follow-up|
|CE-MARC 2||Greenwood (Leeds)||BHF||3T CMR vs. UK NICE guidelines & AHA MPS guidelines in stable CAD (10-90% PTL)||1200||Recruiting. Started Nov 2012||Completed Q1 2015||Leeds, Glasgow, Leicester, Bristol, Oxford, St Georges||In follow-up|
|GADACAD1||Pennell (CI) McCann (UK PI)||Bayer||Diagnostic accuracy of adenosine stress MRI with gadovist in suspected CAD- obtain FDA approval||450||Recruiting commenced Aug 2013 Re-commenced May 2014||Summer 2015||Multinational. UK Siemens Centres: Brompton, Leicester, Bristol, Dundee||Completed analysis underway|
|ACS – TF Lead C Berry|
|CvLPRIT CMR||McCann||NIHR/BHF||Assess infarct size in complete v IRA only revasc in MVD PPCI||203||Completed May 2015||Spring 2015||Leicester, Leeds, Southampton, Harefield, Kettering and Derby||Main results presented ACC 15|
|REFLO-STEMI||Gershlick (Leicester)||NIHR EME||Preven/attenuation of MVO in P-PCI: SNP v Adenosine v routine (inc. thrombus aspn)||246 pts recruited (study closed)||Closed||Results expected Q1 2015||Leicester, Leeds, Newcastle, Walsgrave||Main Results presented ACC 15|
|ERIC||Hausenloy (UCL)||Planned EME Nov 13||Does remote conditioning decr. MI in P-PCI||?2000||Planned submission NIHR EME||N/A||Multicentre||Will combine with Denmark|
|MINIMISE PPCI||Hausenloy (London)||UCL NIHR BRC||Spironolactone prior to PPCI to reduce infarct size LV remodelling||150||?||Basildon, Leeds, London|
|Cardimyopathy – TF Lead S Neubauer|
|HCMR||USA/Oxford||NIH||Identify novel markers in HCM||2750 (>900 enrolled)||Recruiting||N/A||44 N America & Europe|
|VHD – TF Lead G McCann|
|PRIMID AS||McCann (Leicester)||NIHR||Does CMR (3T) MPR superior to ex test in Asymp AS (prognosis)||175||Completed Last 12 month FU Oct 14||Results expected Q2 2015||Leicester, Leeds, Glasgow, Dundee, Aberdeen, + others||Results being prepared for submission|
|TAVI v SAVR||Greenwood (Leeds)||BHF||Efficacy (LV remodelling) and safety (brain injury) TAVI v SAVR||50||Closed||Spring 2014 Results Q2 2015||Leeds, Leicester||Results being prepared for submission|
|BSCMR valve consortium (AS 500)||Greenwood (Leeds)||–||Does LGE predict mortality in patients with severe AS||500 (>300)||Patients being uploaded||Spring 2015||Leeds, Leicester, UCH, Edinburgh, Oxford, Brompton||Centralised de novo analysis of previously recruited research patients|
|CHF – Lead P Leyva|
|Ivabradine HFPEF||McCann (Cleland)||Servier||Assess effect of ivabradine on MPR and LV remodelling in HFPEF||52 (4 recruited)||Closed||End 2015||Leicester, Glasgow, Dundee, London Chest, Aberdeen, Hull, Birmingham||Poor recruitment|